Invests in companies involved in genomic sequencing. Targets firms developing gene editing technologies. Now — the numbers.
The stock trades 42% below its peak. The market has trimmed its expectations for the company.
This is a fund, not a company — there are no company accounts here to point to a strength. What it holds is what it is.
This stock swings about 2.4 times as much as the market average. Big rallies — and big drops — can both happen fast.
We grade companies — revenue, margins, balance sheets. This is a fund, so there is no report card to give. That is not a low grade; it is a different kind of thing.
One-line summary: a basket, not a business. Judge it by what it holds.